Crucell corporate brochure (PDF)

Overview – Crucell: A global perspective
Research and development
Vaccines in development:
Flavimun® yellow fever vaccine.
Influenza Seasonal cell-based seasonal vaccine.
Universal Influenza cell-based
universal vaccine.
Tuberculosis recombinant AdVac®based
vaccine.
Malaria recombinant AdVac®based
vaccine.
Ebola and Marburg recombinant AdVac®based
vaccine.
Technologies
PER.C6® human cell line for development
and manufacturing.
AdVac® used with PER.C6® to develop
recombinant vaccines.
MAbstract® to discover novel drug targets
and identify human monoclonal antibodies.
Products
Paediatric:
Quinvaxem® fully liquid vaccine to protect
against five important childhood diseases.
Hepavax-Gene® recombinant hepatitis B
vaccine.
Epaxal® Junior low dosage, aluminum-free
hepatitis A vaccine.
MoRu-Viraten® vaccine for protection
against measles and rubella.
HIV recombinant AdVac®-based vaccine.
HPV recombinant AdVac®-based vaccine.
RSV recombinant AdVac®-based vaccine.
Human monoclonal antibodies
in development:
Rabies antibody combination.
Influenza antibodies.
Hepatitis C antibody combination.
Details on page 12
STAR® to enhance yields of recombinant
human antibodies and proteins.
Virosome a vehicle enabling the use of
virus antigens in the making of vaccines.
Details on page 20
Travel and endemic:
Epaxal® aluminum-free hepatitis A vaccine.
Vivotif® oral typhoid vaccine.
Dukoral® only internationally licensed
oral vaccine against cholera (and ETEC).
Respiratory:
Inflexal® V virosomal adjuvanted
influenza vaccine.
Details on page 26
07